- MSKCC is profiled in a New York Times article about major academic medical centers in New York and around the country that are spending and recruiting heavily on genomic sequencing programs.
- Researchers from Cornell and MSKCC have published results of a study that revealed that spongelike nanoparticles whose pores can be filled with drugs may offer the promise of drug delivery to specific targets in the body.
- Genetically engineered immune cells can drive an aggressive type of leukemia into retreat, an MSKCC clinical trial suggests.
- Charles Sawyers of MSKCC is quoted in a Nature article advocating for cancer researchers to focus on single-subject, or ‘n-of-1’, studies that could offer new insights into cancer.
- A new study published in the British Medical Journal from researchers at MSKCC suggest that aside from men with a history of prostate cancer, other groups at high risk for the disease may be identified with a single PSA test when they are in their 40s.
Category Archives: MSK in the News
MSKCC in the News: February 21 – March 6
- Initiated by Zanofi’s decision to cut in half the price of Zaltrap after MSKCC said it would not use the drug because it was too expensive, the Health Affairs Blog examines how the “buy and bill” pricing system works, and how it operates in the case of Zaltrap.
- Medgadget reports that IBM’s work with WellPoint and MSKCC on the development of Watson has progressed beyond concept. Now, hospitals and other provider institutions who sign up can buy or rent Watson’s advice from the cloud or their own server.
- The Digital Journal announced that physicians at MSKCC will begin the “first-in-man” drug therapy on mesothelioma patients.
MSKCC in the News: February 14 – February 20
- Westchester Medical Center (WMC) has announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with MSKCC, whose staff will provide outpatient cancer care and infusion services.
- Dr. Michael J. Morris of MSKCC was quoted in a New York Times article about a new study that found that men with high-risk prostate cancer treated with only 18 months of hormone therapy live just as long as those treated for a more standard 36 months.